Datasets:
smiles large_stringlengths 1 1.05k | oral_bioavailability_value float64 0 942 | canonical_endpoint_key large_stringclasses 2
values | endpoint_family large_stringclasses 1
value | endpoint_subtype large_stringclasses 2
values | unit_basis large_stringclasses 1
value | species_exact large_stringclasses 48
values | scalar_value float64 0 942 | unit_normalized large_stringclasses 1
value | scalar_is_approximate bool 1
class | molecule_name large_stringlengths 1 192 | bioavailability_report_type large_stringclasses 2
values | species_or_population large_stringlengths 2 157 ⌀ | dose large_stringlengths 1 107 ⌀ | oral_exposure_mode large_stringlengths 2 158 ⌀ | qualifying_conditions large_stringlengths 2 207 ⌀ | comparator large_stringlengths 2 85 ⌀ | species_or_population_normalized large_stringclasses 15
values | condition_key_repro large_stringlengths 22 263 ⌀ | pmid large_stringlengths 5 8 | source_id large_stringclasses 1
value | source_name large_stringclasses 1
value | record_id large_stringlengths 64 64 | source_row_number int64 1 49.2k | input_sha256 large_stringclasses 1
value | parent_provenance_id large_stringlengths 64 64 | child_id large_stringlengths 64 64 | extra_details large_stringlengths 3 318 ⌀ | support_text large_stringlengths 29 481 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1 | 88 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 88 | percent | false | solifenacin | absolute | healthy volunteers | 10mg | oral | null | 5mg iv dose | human | healthy volunteers | oral | not specified | 5mg iv dose | 15293866 | starling | starling_oba | b17248363323cee8df278636d6c4bd423217358ffc4f3a25c5f96a8c7fd1009e | 1 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | b17248363323cee8df278636d6c4bd423217358ffc4f3a25c5f96a8c7fd1009e | f0188a2c69159fe7ec04bb17674a1bc4cacf30dc96a49890b1eb77046badebca | The value was close to the value predicted from oral data alone (approximately 87%). | The absolute oral bioavailability of solifenacin was determined to be 88% in healthy volunteers following a single 10mg oral dose compared to a single 5mg IV dose, which was close to the value of approximately 87% predicted from oral data alone. |
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1 | 65 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 65 | percent | false | canagliflozin | absolute | participants | 300 mg | null | null | vs iv | human | participants | not specified | not specified | vs iv | 27136910 | starling | starling_oba | aa2749798c5223b5e585723a2df3094245ad440bd52e50ae046dbca181467cd9 | 2 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | aa2749798c5223b5e585723a2df3094245ad440bd52e50ae046dbca181467cd9 | 60c1573de053c6987347251c79068abd891b7695401491deb7b111dabfc904ea | Calculated using geometric mean ratio estimates of AUC∞. | Based on the comparison of geometric mean ratio estimates of AUC∞ of oral and dose-normalized intravenous infusion of canagliflozin, the mean absolute oral bioavailability of canagliflozin was 65% (90% CI: 55.41; 76.07). |
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C | 27 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | dog | 27 | percent | false | Medroxyprogesterone acetate | absolute | dogs | 2.5, 5, and 10 mg | tablets | null | vs iv | dog | dogs | tablets | not specified | vs iv | 8499584 | starling | starling_oba | ff92503280827f45969bf0d09345e9c7e9fdff4b33f27f3409e2a22d066952a4 | 3 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | ff92503280827f45969bf0d09345e9c7e9fdff4b33f27f3409e2a22d066952a4 | a40c9f43d95b960a26d5866f0082589f2b70371fd66a4c111a3c6561e8d2fcb0 | Oral absorption was reported to be dose-linear over the studied dosage range. | In dogs, the oral absorption of Medroxyprogesterone acetate (MPA) appeared to be dose-linear over the studied dosage range (2.5, 5, and 10 mg tablets), and the absolute bioavailability was estimated at 27 per cent compared to an intravenous dose. |
CC(C)Nc1ccc(OC(C)C(=O)O)cc1 | 3 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | pig | 3 | percent | false | metoprolol | absolute | anaesthetised göttingen mini-pigs | null | oral administration | null | buccal dosing (58-107%) | pig | anaesthetised göttingen mini-pigs | oral administration | not specified | buccal dosing (58-107%) | 23500040 | starling | starling_oba | 0afbea79b7c35c87a05f87421f9d7d76c86cea4cb4a7678c95836ffb4485177c | 5 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 0afbea79b7c35c87a05f87421f9d7d76c86cea4cb4a7678c95836ffb4485177c | 600b80501b6dc5f8ef414b1eeb1f461025d375ddd0b5a8bbb3c33dedb1fbfffd | null | In anaesthetised Göttingen mini-pigs, metoprolol showed an absolute bioavailability of 3% following oral administration, which was significantly lower than the 58–107% observed after buccal dosing. |
O=C(O)c1ccc(CCN(CCc2ccccc2OCc2ccc(-c3ccc(C(F)(F)F)cc3)cc2Cl)[C@H]2CCCc3nc(C(=O)O)ccc32)cc1 | 23 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 23 | percent | false | Mosliciguat | absolute | enrolled subjects | null | null | null | null | human | enrolled subjects | not specified | not specified | not specified | 40402373 | starling | starling_oba | 284e6faae1db98471648403490c5aa9a3cad1cd6bb3f532c6d6b0255e9c7f560 | 6 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 284e6faae1db98471648403490c5aa9a3cad1cd6bb3f532c6d6b0255e9c7f560 | 442368269ee58d686e178c9a120208766d40f039a7c000fa2288770423f9ddd3 | null | Absolute bioavailability for oral mosliciguat was reported to be 23%. |
O=C(O)c1ccc(CCN(CCc2ccccc2OCc2ccc(-c3ccc(C(F)(F)F)cc3)cc2Cl)[C@H]2CCCc3nc(C(=O)O)ccc32)cc1 | 23.1 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 23.1 | percent | false | Mosliciguat | absolute | healthy male volunteers | 1000 μg | oral solution | null | vs iv | human | healthy male volunteers | oral solution | not specified | vs iv | 40402373 | starling | starling_oba | b4cafd84e01b773b0c20edd832082608b2dd4847956d54f7467552d1f8d7358f | 7 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | b4cafd84e01b773b0c20edd832082608b2dd4847956d54f7467552d1f8d7358f | 043ce6b3089fc5f5f6919f573bdc1ef13dbd5eb5e9e52186845549b01469ce69 | Study 1 (Part 2); IV dose was 100 μg | In Study 1 (Part 2), the absolute bioavailability of oral mosliciguat was 23.1% in healthy male volunteers. This was based on a 1000 μg oral solution dose compared to a 100 μg intravenous dose. |
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1 | 90 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 90 | percent | false | solifenacin | absolute | null | null | null | not decreased by multiple dosing and concomitant food intake | null | null | null | 19566112 | starling | starling_oba | 74a2e592cfbe001467dc58f2b0ae6d985e488b0045405c473f64abec82f5f4b1 | 8 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 74a2e592cfbe001467dc58f2b0ae6d985e488b0045405c473f64abec82f5f4b1 | ce2239bb1f3cbe1b9bb066376773d2ebacca4b1e70a6cd333082299c1bcfe298 | null | Orally administered solifenacin has a high absolute bioavailability of 90%, which is not decreased by multiple dosing and concomitant food intake. |
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C | 69.8 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 69.8 | percent | false | osimertinib | absolute | healthy subjects | 80-mg | null | null | vs iv microtracer dose of [14c]osimertinib | human | healthy subjects | not specified | not specified | vs iv microtracer dose of [¹⁴c]osimertinib | 29683562 | starling | starling_oba | 46d5df4923e75e7dae943680c993e01f408577e671ac747dba7bb961f8cc5aeb | 9 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 46d5df4923e75e7dae943680c993e01f408577e671ac747dba7bb961f8cc5aeb | d9a81e3595a0f7f8b4c6a0672c57defb635e865c294d8c607d537149c92f9957 | Geometric mean absolute oral bioavailability. | In a phase I study, ten healthy subjects (21–61 years) received a single oral 80-mg dose of osimertinib concomitantly with a 100 µg IV microtracer dose of [¹⁴C]osimertinib. The geometric mean absolute oral bioavailability of osimertinib was 69.8% (90% confidence interval, 66.7, 72.9). |
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)C=C[C@H]3[C@H]1C5 | 11 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 11 | percent | false | M6G | absolute | volunteers | 20 mg | p.o. | null | vs i.v. | human | volunteers | p.o. | not specified | vs i.v. | 11966664 | starling | starling_oba | d371bee531dcfeeff0e723dfc03e48c6b517c49864519451fc5392d29517761b | 11 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | d371bee531dcfeeff0e723dfc03e48c6b517c49864519451fc5392d29517761b | 64da2b2c940c1441c8d65bb08b41b5e2ebab32a9a28931d74275dee79baf94ea | 90% CI: 9–12%; bioavailability derived using AUC(0,t_n) values. | In a study of 10 volunteers, the oral (p.o.) administration of 20 mg of M6G resulted in a mean absolute bioavailability F(0, ∞) of 11 ± 3% (90% CI 9–12%), calculated using AUC(0,t_n) values. |
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC | 55 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | human | 55 | percent | false | fostamatinib | absolute | human | null | null | null | null | human | human | not specified | not specified | not specified | 27858108 | starling | starling_oba | 88780609d698f9edae053eb0916d2b9b5763e3ebaccacbe6511acc0146872b6e | 12 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 88780609d698f9edae053eb0916d2b9b5763e3ebaccacbe6511acc0146872b6e | 5ff629201f443d2ed4fe8138e220d58c52e5e602470f96e8012688bb1b8bc91d | null | The absolute oral bioavailability of fostamatinib was ~55%. |
COc1ccc(-c2nc3cc(C4=NNC(=O)CC4C)ccc3[nH]2)cc1 | 70 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | dog | 70 | percent | false | Pimobendan | absolute | healthy dogs | 0.25 mg/kg | p.o. | null | vs iv | dog | healthy dogs | p.o. | not specified | vs iv | 25989021 | starling | starling_oba | f9faad2d0de34b83af4af3166d296a174813b79882bf4d10aebc80fab055108e | 13 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | f9faad2d0de34b83af4af3166d296a174813b79882bf4d10aebc80fab055108e | 2742f56633bf4e46e740b354adaa8830003eb5b6427cf8c8cd0dad10f1063e29 | Intravenous dose was 0.125 mg/kg. | The bioavailability of pimobendan after oral dosing (0.25 mg/kg) in healthy dogs was 70%, with an intravenous dose of 0.125 mg/kg used as a comparator. |
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1 | 65 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 65 | percent | false | canagliflozin | absolute | healthy men | 300 mg | oral | null | intravenous [14c]-canagliflozin | human | healthy men | oral | not specified | intravenous [¹⁴c]-canagliflozin | 27136910 | starling | starling_oba | 5ace889ef35b6892f7b7e95721a1c17df12ac8d840ea592bd8177c4e05e9cd75 | 14 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 5ace889ef35b6892f7b7e95721a1c17df12ac8d840ea592bd8177c4e05e9cd75 | 215eb90c0c5d5183c1204635577e96130ac538fe77a136276b04c1823acd994d | Assessed via simultaneous oral administration with intravenous [¹⁴C]-canagliflozin microdose infusion (10 µg) in nine healthy men. | The absolute oral bioavailability of canagliflozin was 65% (90% confidence interval: 55.41; 76.07) following a single-dose oral administration of 300 mg in nine healthy men, assessed using a simultaneous intravenous [¹⁴C]-canagliflozin microdose infusion. |
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1 | 88 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 88 | percent | false | solifenacin | absolute | healthy male volunteers | 10mg | null | null | vs iv | human | healthy male volunteers | not specified | not specified | vs iv | 15293866 | starling | starling_oba | b9cb04d2490b370df2efea34e318b0e89525f5d5a9b428b87e82f76944894031 | 15 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | b9cb04d2490b370df2efea34e318b0e89525f5d5a9b428b87e82f76944894031 | c8051f4c74da9868b2815a1f629204b48292a8bf18a245bb7c74c6ff338073bd | Calculated as oral (AUC∞/dose) divided by IV (AUC∞/dose). | In a study with healthy male volunteers, the absolute bioavailability of solifenacin following a 10mg oral dose was 88.0% (95% CI 75.8, 102.1), calculated as the ratio of oral (AUC∞/dose) to IV (AUC∞/dose). |
CN1CCCC1c1cccnc1.O=C(O)C(O)C(O)C(=O)O | 41 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | human | 41 | percent | false | nicotine tartrate | absolute | healthy human subjects | 3 mg | delayed-release oral capsules | ileocolonic delivery, eudragit s100 coated | vs intravenous nicotine tartrate | human | healthy human subjects | delayed-release oral capsules | ileocolonic delivery, eudragit s100 coated | vs intravenous nicotine tartrate | 9354194 | starling | starling_oba | 846744f7fc87266a3082a0aec90c308ddc6770a64535cc309d50662c996f0492 | 16 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 846744f7fc87266a3082a0aec90c308ddc6770a64535cc309d50662c996f0492 | f02921fa9e1c940c4c72a4bece287eb6c58a1262c5b12b7ae5d332220833c840 | reported as mean bioavailability | The mean bioavailabilities of nicotine after ileocolonic nicotine tartrate administration via delayed-release oral capsules at a dose of 3 mg nicotine were 41%. This was determined in twenty healthy human subjects who also received intravenous nicotine tartrate. |
CN1CCCC1c1cccnc1.O=C(O)C(O)C(O)C(=O)O | 42 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | human | 42 | percent | false | nicotine tartrate | absolute | healthy human subjects | 6 mg | delayed-release oral capsules | ileocolonic delivery, eudragit s100 coated | vs intravenous nicotine tartrate | human | healthy human subjects | delayed-release oral capsules | ileocolonic delivery, eudragit s100 coated | vs intravenous nicotine tartrate | 9354194 | starling | starling_oba | 3483057c1a4242b117af8a6613838188dcb10e7ee494577ebbf9801a1cbd2487 | 17 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 3483057c1a4242b117af8a6613838188dcb10e7ee494577ebbf9801a1cbd2487 | 8a4d1fb17b768e51ad6373b2e57d3b8e4873d26f3ecf95c6b7e6b5281b627368 | reported as mean bioavailability | The mean bioavailabilities of nicotine after ileocolonic nicotine tartrate administration via delayed-release oral capsules at a dose of 6 mg nicotine were 42%. This was determined in twenty healthy human subjects who also received intravenous nicotine tartrate. |
Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O | 100 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 100 | percent | false | flavoxate | absolute | healthy male volunteers | 2.55 ± 0.14 mg/kg | oral | null | vs iv | human | healthy male volunteers | oral | not specified | vs iv | 14606931 | starling | starling_oba | e3d3c3937691a92d76f01cf5f9ecdfe546af55e79055b738ee8043822a19d3e8 | 18 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | e3d3c3937691a92d76f01cf5f9ecdfe546af55e79055b738ee8043822a19d3e8 | 7320a5e13438ef5f4c2410d7f90733906202bb8e66b838e57c7e5c06bbae4d8f | Calculated based on a comparison of oral and intravenous data in different subjects. | Oral bioavailability of flavoxate, based on a comparison of oral and intravenous data in different healthy male volunteers receiving oral doses of 2.55 ± 0.14 mg/kg, appeared to be close to 100%. |
CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O | 102.7 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 102.7 | percent | false | ibuprofen lysine | absolute | healthy male volunteers | 500 mg | coated tablets | lysine salt | intravenous injections of ibuprofen solutions | human | healthy male volunteers | coated tablets | lysine salt | intravenous injections of ibuprofen solutions | 2109643 | starling | starling_oba | 63a7e6e9e2e19f2387c84b36270054bb7040359b8f2561e21e94ddb595d790c0 | 19 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 63a7e6e9e2e19f2387c84b36270054bb7040359b8f2561e21e94ddb595d790c0 | fc482ae9600a81cc9f1952430c0c95c9900fe06ee824183ddd1a531b0ef9ebd4 | indicating a complete absorption of ibuprofen; sample size of 8 volunteers | In a study involving 8 healthy male volunteers, the absolute bioavailability of ibuprofen administered as a single oral dose of 500 mg of ibuprofen lysine (via coated tablets) was determined to be 102·7 per cent, indicating complete absorption, using intravenous injections of ibuprofen solutions as a reference. |
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F | 40 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 40 | percent | false | idasanutlin | absolute | patients | 300 mg | sdp formulation | sdp formulation | vs iv tracer dose (100 μg) | human | patients | sdp formulation | sdp formulation | vs iv tracer dose (100 µg) | 31062077 | starling | starling_oba | ae81834344aeef521d03806ef815a23e3bf7764a07fe05180944c2748871fab8 | 22 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | ae81834344aeef521d03806ef815a23e3bf7764a07fe05180944c2748871fab8 | a6d91f594c6e3f2dae236a02e7cac12c0badaf05fb38b3292488bc3730806e8d | Co-administered with a single oral dose of 100 mg MBP. | In a study involving patients, co-administration of an IV tracer dose (100 µg) with a single oral dose of 100 mg MBP and 300 mg SDP idasanutlin resulted in the absolute bioavailability of idasanutlin SDP of ~40%. |
O=c1c(-n2ccnn2)c[nH]n1-c1cc(N2CCOCC2)ncn1 | 59 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 59 | percent | false | Molidustat | absolute | participants | 50 mg | ir tablet formulation | null | vs iv | human | participants | ir tablet formulation | not specified | vs iv | 32248614 | starling | starling_oba | 0c9ed16e5a0c545517b95b37c1c34bf8b41065c11d3ca7a309bfff2088ef2528 | 25 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 0c9ed16e5a0c545517b95b37c1c34bf8b41065c11d3ca7a309bfff2088ef2528 | 46fe26dedf3b916ba47bc5ae42eaa18c60d613b2d98e0de3dcf8a93cba5122eb | Sample size n = 16. | The absolute bioavailability of molidustat 50 mg administered orally as an IR tablet formulation was 59.0% (90% CI: 55.3%-63.0%) compared to intravenous administration. |
O=c1c(-n2ccnn2)c[nH]n1-c1cc(N2CCOCC2)ncn1 | 59 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 59 | percent | false | Molidustat | absolute | participants | 50 mg | ir tablet formulation | null | null | human | participants | ir tablet formulation | not specified | not specified | 32248614 | starling | starling_oba | 3933fff04e955cd50355661e7610b0dbeba7030225c7b6bef8caeed3aa7d7c01 | 26 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 3933fff04e955cd50355661e7610b0dbeba7030225c7b6bef8caeed3aa7d7c01 | 7680b1ec1434789d4ad1b71f144535acff4da822957785a389cc608996cfedfc | null | Molidustat has an absolute bioavailability of 59% when orally administered as an IR tablet formulation at a dose of 50 mg. |
Cc1cccc2sc3nncn3c12 | 93.9 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 93.9 | percent | false | tricyclazole | absolute | rat | 2 mg/kg | gavage | null | vs iv | rodent | rat | gavage | not specified | vs iv | 31461669 | starling | starling_oba | 02c4427ff200df327ada02a7a8ad9e626c264f5c85de9f1bd5e250e79979e2f4 | 27 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 02c4427ff200df327ada02a7a8ad9e626c264f5c85de9f1bd5e250e79979e2f4 | c41ff85ab50abbbec895a721af5fdb2122a9d73472877b083e1e614794d5bbd4 | AUC0-tlast values were 11.7 µg h/ml for the oral group and 12.5 µg h/ml for the IV group; study performed in Rat Fischer 344. | In the oral bioavailability study from Johnson et al. (2004), based on AUC values determined from ¹⁴C-tricyclazole equivalent concentration time curves, the absolute bioavailability for tricyclazole was 93.9% in rats following gavage administration compared to intravenous administration. |
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1 | 36 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 36 | percent | false | Ticagrelor | absolute | healthy volunteers | null | null | null | iv | human | healthy volunteers | not specified | not specified | iv | 27536453 | starling | starling_oba | 048abaeabc3408afbc7d2c7d0475a7514a633e1d33a6eecd0430b2d6c28a915b | 28 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 048abaeabc3408afbc7d2c7d0475a7514a633e1d33a6eecd0430b2d6c28a915b | 973057ce09b715abf1720c97fdc0713201558a1f975603ef44b7bb9c30f084b2 | The study that determined this value was the first to determine the pharmacokinetics of ticagrelor following IV administration. | In a study of healthy volunteers, the mean absolute bioavailability of ticagrelor was found to be 36% (95% CI = 30–42). |
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13 | 94.5 | starling.oral_bioavailability.systemic_availability.percent | oral_bioavailability | systemic_availability | percent | dog | 94.5 | percent | false | [¹⁴C]EP | systemic availability | dog | null | oral administration | null | null | dog | dog | oral administration | not specified | not specified | 11205738 | starling | starling_oba | 049b5fd46a169e54b2fb6d05a47ee31b3bae4b2c2796d65479fa957a978e35be | 29 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 049b5fd46a169e54b2fb6d05a47ee31b3bae4b2c2796d65479fa957a978e35be | 9f53428fc1992ede893a7a905d1db8690d2cb1dd59312c9e59e7e75104e32d15 | Reported as the systemic availability of total radioactivity. | After oral administration of [¹⁴C]EP in the dog, the systemic availability of total radioactivity was 94.5 ± 6.6%, indicating good absorption. |
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13 | 79.2 | starling.oral_bioavailability.systemic_availability.percent | oral_bioavailability | systemic_availability | percent | dog | 79.2 | percent | false | EP | systemic availability | dog | null | oral administration | null | null | dog | dog | oral administration | not specified | not specified | 11205738 | starling | starling_oba | 087e8219502c3641d3b714ea0ab437d2ccf5b5cac65be5b7f17491bbfc458b57 | 30 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 087e8219502c3641d3b714ea0ab437d2ccf5b5cac65be5b7f17491bbfc458b57 | 075dce6bca1f5845b312713a6a4da157ab898e2ec77b496cdfc3e3a14180224e | null | Following oral administration in dogs, the systemic availability of EP was 79.2%. |
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13 | 90 | starling.oral_bioavailability.systemic_availability.percent | oral_bioavailability | systemic_availability | percent | dog | 90 | percent | false | total EP | systemic availability | dog | null | oral administration | null | null | dog | dog | oral administration | not specified | not specified | 11205738 | starling | starling_oba | b3de993148c672ba01b3c80984c24e01b8d935731422c32954b47bdea35ca5bf | 31 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | b3de993148c672ba01b3c80984c24e01b8d935731422c32954b47bdea35ca5bf | 37630ce937f6613a4210681ce11e6147e9818d2fce70dff782de553b099e808a | null | The mean systemic availability of total EP after oral administration in dogs was 90.0%, indicating good absorption of EP. |
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C | 69.8 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 69.8 | percent | false | osimertinib | absolute | healthy subjects | 80-mg | single oral dose | null | vs [14c] radiolabeled iv microtracer dose | human | healthy subjects | single oral dose | not specified | vs [¹⁴c] radiolabeled iv microtracer dose | 29683562 | starling | starling_oba | 0bb7838a7dea017592c5555e51bd3b10b73e8f204a2ede2bb31622525489d4e4 | 32 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 0bb7838a7dea017592c5555e51bd3b10b73e8f204a2ede2bb31622525489d4e4 | e4740986cfd00c147d777b6755883b27416dd187ee3da633f4baa634fb62ee38 | suggesting that osimertinib is well absorbed in humans | The oral absolute bioavailability of an 80-mg single oral dose of osimertinib in healthy subjects was 69.8%, suggesting that osimertinib is well absorbed in humans. |
O=C1N(c2ccccc2)CCN1c1ccccc1 | 87.5 | starling.oral_bioavailability.systemic_availability.percent | oral_bioavailability | systemic_availability | percent | null | 87.5 | percent | false | Phenytoin | systemic availability | null | null | oral administration | products with high quality | null | null | null | 378503 | starling | starling_oba | 997d28e0b35e6e428ca94ad73b691378e735a6e739b0fbdeaad67c509527b900 | 34 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 997d28e0b35e6e428ca94ad73b691378e735a6e739b0fbdeaad67c509527b900 | 233e6edbdaf56b9a63c37184659f0a14a176a775e94476d23a8a13c3388cc0cb | The author notes that no significant first-pass metabolism occurs during gastrointestinal absorption. | The systemic bioavailability of phenytoin is of the order of 80 to 95% after the oral administration of products with high quality, which suggests that there is no significant first-pass metabolism during gastrointestinal absorption. |
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1 | 36 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 36 | percent | false | Ticagrelor | absolute | individuals | 90 mg | null | null | vs iv | human | individuals | not specified | not specified | vs iv | 27536453 | starling | starling_oba | cdbe98b9f6b3968c914143132239bcb1b22a7ac2d7a21cdaf64048e2f061e5cb | 37 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | cdbe98b9f6b3968c914143132239bcb1b22a7ac2d7a21cdaf64048e2f061e5cb | c76ccab922783dcbf94f050ed211442346eb4f17f8658e009969b040f0b7f22c | Bioavailability in individuals ranged from 25.4–64.0%; the dose used for the oral administration was 90 mg as specified in the associated pharmacokinetic data. | The mean absolute bioavailability of ticagrelor was 36% (95% confidence interval [CI] = 30–42%), with bioavailability in individuals ranging from 25.4–64.0%. |
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23 | 99 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 99 | percent | false | Levofloxacin | absolute | null | 500-1000mg once daily | oral administration | null | intravenous | null | null | 14664657 | starling | starling_oba | 553096c07a1ef6eb023577adb76cd62acc103821ac7098777e654c3a8f044648 | 38 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 553096c07a1ef6eb023577adb76cd62acc103821ac7098777e654c3a8f044648 | 2d708ec8c72feb82c390385576bb85d10e311638890828f5c02a4db6eb672535 | pharmacokinetics are linear over the dosage range 500–1000mg once daily for multiple-dose administration; oral and intravenous routes are considered interchangeable | Levofloxacin is rapidly absorbed after oral administration, with an absolute bioavailability of approximately 99%. Its pharmacokinetics are linear over the dosage range of 500–1000mg once daily for multiple-dose administration, and the oral and intravenous routes are considered interchangeable. |
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2 | 11 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 11 | percent | false | mycophenolate mofetil | absolute | null | null | oral administration | null | vs intravenous administration | null | null | 8728345 | starling | starling_oba | f17ef84ea437fe398cc92f88bc0477202466b78df8f0e58b5ef0ce30c6fd7b93 | 39 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | f17ef84ea437fe398cc92f88bc0477202466b78df8f0e58b5ef0ce30c6fd7b93 | d04276d735964db5ca052c9088c3a72fc044c8e3a296192a170dbc2d064eca28 | This value represents the upper limit based on the ratio of plasma Cmax values (0.4/3.5). | The upper limit of the absolute bioavailability of MMF after oral administration (based on the ratio of plasma Cmax values for MMF) was therefore 0.4/3.5, or 11%. |
[O-][Cl+][O-] | 23 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | mouse | 23 | percent | false | MnTE-2-PyP⁵⁺ | absolute | mice | 10 mg/kg | oral gavage | null | vs iv | rodent | mice | oral gavage | not specified | vs iv | 23328731 | starling | starling_oba | d86864b2d7a2b24a002d5a91ed79ea771104964dd22ed609ad12a1ce408878f1 | 41 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | d86864b2d7a2b24a002d5a91ed79ea771104964dd22ed609ad12a1ce408878f1 | febe7900f0b30fbaacea0838d9ed19fe35c4e6b532a844ebfdb43fa43dc4a675 | Calculated using AUC ratio; intravenous dose was also 10 mg/kg. | For MnTE-2-PyP⁵⁺ in mice, an oral availability of 23% was calculated using identical oral and intravenous doses of 10 mg/kg. |
O=[N+]([O-])[O-] | 21 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | mouse | 21 | percent | false | MnTnHex-2-PyP⁵⁺ | absolute | mice | 2 mg/kg | oral gavage | null | vs iv | rodent | mice | oral gavage | not specified | vs iv | 23328731 | starling | starling_oba | 18ab0cb0e23d52f3d1c4350943407bb18debe05b30e8471ea0cbeeeba98fad3e | 42 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 18ab0cb0e23d52f3d1c4350943407bb18debe05b30e8471ea0cbeeeba98fad3e | f129cc634a07cd825ccb386ba4aa1ff4f5a2ee82be9b7c56b04794d7241e94e0 | Calculated using AUC ratio; intravenous dose was limited to 0.5 mg/kg due to toxicity (blood pressure drop). | The oral availability of MnTnHex-2-PyP⁵⁺ in mice was determined to be 21%, based on an oral dose of 2 mg/kg and an intravenous dose of 0.5 mg/kg. |
C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1 | 22.8 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 22.8 | percent | false | Traxoprodil | absolute | cyp2d6 extensive metabolisers | 50mg | po | null | vs 100mg iv | null | cyp2d6 extensive metabolisers | po | not specified | vs 100mg iv | 16984212 | starling | starling_oba | 68bf1c079ca2251ffd4d7f41a153258a43bdbf14f9f1ccec32bac2c938c890ad | 43 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 68bf1c079ca2251ffd4d7f41a153258a43bdbf14f9f1ccec32bac2c938c890ad | 9afd3e60b6f7f3f5066a8cb6d2252bd111277e0da28db36aad72c4eedf2be9d8 | Sample size n = 3; bioavailability calculated based on the 100mg intravenous dose. | In CYP2D6 extensive metabolisers, the absolute oral bioavailability (F) of traxoprodil after a 50mg oral (PO) dose was 22.8%. |
C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1 | 39.5 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 39.5 | percent | false | Traxoprodil | absolute | cyp2d6 extensive metabolisers | 100mg | po | null | vs 100mg iv | null | cyp2d6 extensive metabolisers | po | not specified | vs 100mg iv | 16984212 | starling | starling_oba | 16fc9680ad187887c377e62c83fd1242bc01612d3d44a0c4b5a7f37462c273a0 | 44 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 16fc9680ad187887c377e62c83fd1242bc01612d3d44a0c4b5a7f37462c273a0 | ac7ebaa8146da6536f3bafbfac67eea3aa66e3d9ad7602e1a8e83e269f7b2319 | Sample size n = 10; bioavailability calculated based on the 100mg intravenous dose. | In CYP2D6 extensive metabolisers, the absolute oral bioavailability (F) of traxoprodil after a 100mg oral (PO) dose was 39.5 (20.1)%. |
C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1 | 62.1 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 62.1 | percent | false | Traxoprodil | absolute | cyp2d6 extensive metabolisers | 300mg | po | null | vs 100mg iv | null | cyp2d6 extensive metabolisers | po | not specified | vs 100mg iv | 16984212 | starling | starling_oba | d880927ef644637769e2bef5223cbb907ffa96cfe405334dbf0f779af5f7de93 | 45 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | d880927ef644637769e2bef5223cbb907ffa96cfe405334dbf0f779af5f7de93 | 619754ad2f5a173479cc3331e66bbdecc3bdd296e738c04d357166b89e043bcb | Sample size n = 5; bioavailability calculated based on the 100mg intravenous dose. | In CYP2D6 extensive metabolisers, the absolute oral bioavailability (F) of traxoprodil after a 300mg oral (PO) dose was 62.1 (26.9)%. |
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1 | 88 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 88 | percent | false | solifenacin | absolute | healthy men | 10mg | null | null | vs iv | human | healthy men | not specified | not specified | vs iv | 15293866 | starling | starling_oba | b73c31d9ca23857465fb43fe47ccfb0fed9216b88e1123c2b07da55869454702 | 49 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | b73c31d9ca23857465fb43fe47ccfb0fed9216b88e1123c2b07da55869454702 | 900642dd2b6c9d16050a41c1d327f1b5f681f0ef5b0950bd2fb96a80a9be73a3 | Bioavailability was calculated by comparing plasma concentrations after a 10mg oral dose and a 5mg IV dose. | Pharmacokinetic analyses of twelve healthy men (aged 20–45 years) demonstrated that solifenacin has a high absolute oral availability of 88%, determined by comparing a single 10mg oral dose with a single 5mg intravenous (IV) dose. |
O=C([O-])c1ccc(/C=C/S(=O)(=O)Cc2ccc(Cl)cc2)cc1.[Na+] | 30 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 30 | percent | false | ON 01210.Na | absolute | monkeys | 125 mg/kg | 50% peg | null | i.v. | monkey | monkeys | 50% peg | not specified | i.v. | 21341279 | starling | starling_oba | 73856f53478618dde7be96f8b0fd6b0ab7fb2364f30cb1cfe08da00a7acab209 | 55 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 73856f53478618dde7be96f8b0fd6b0ab7fb2364f30cb1cfe08da00a7acab209 | d35faa5d35af8eb2973f7965fc999deb1a039c561ff161de05a90f1e4acb262a | Cmax: 28.6 (4.87) µg/ml, AUC: 154 (14.5) µg*h/ml; bioavailability estimated based on ratio of dose-normalized AUC. | Following p.o. administration of a 50% PEG formulation of ON 01210.Na to monkeys at a dose of 125 mg/kg, the bioavailability was 30%, calculated based on the ratio of dose-normalized AUC compared with i.v. dosing. |
C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1 | 80 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 80 | percent | false | Traxoprodil | absolute | healthy male volunteers | 50, 100 and 300mg | solution | cyp2d6 poor metabolisers | iv | human | healthy male volunteers | solution | cyp2d6 poor metabolisers | iv | 16984212 | starling | starling_oba | 2d13447a00009e7531906f68b176f7459518a3668b3be7027a7223219bc63640 | 56 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 2d13447a00009e7531906f68b176f7459518a3668b3be7027a7223219bc63640 | ca5ee6e30b61ff98cd04dca41a808b0845f224115a9ea5e79e0ce56888a7a110 | Sample size n = 6; consistent with a liver extraction ratio of ~20% (plasma clearance of ~4 mL/min/kg), indicating near complete absorption. | In poor metabolisers (n = 6), the oral bioavailability of traxoprodil was ~80%, which was consistent with a liver extraction ratio of ~20% and indicated near complete absorption. |
C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1 | 39.5 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 39.5 | percent | false | Traxoprodil | absolute | healthy male volunteers | 100mg | solution | cyp2d6 extensive metabolisers | iv | human | healthy male volunteers | solution | cyp2d6 extensive metabolisers | iv | 16984212 | starling | starling_oba | cb39718cf325ca319e5e5ac9c1331cb1d7fba3bda62b021a3e1ba10a8761d1e8 | 57 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | cb39718cf325ca319e5e5ac9c1331cb1d7fba3bda62b021a3e1ba10a8761d1e8 | a2fb20ae4f29b018da26ba572d156af4b3d7ad8410ca2c06c1b26a7166983b2c | Sample size n = 11; oral bioavailability was reported as dose-dependent and nonlinear in this population. | In extensive metabolisers (n = 11), traxoprodil oral bioavailability was dose-dependent and nonlinear; at the 100mg dose, the absolute oral bioavailability was ~39.5%. |
C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1 | 22.8 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 22.8 | percent | false | Traxoprodil | absolute | healthy male volunteers | null | solution | cyp2d6 extensive metabolisers | iv | human | healthy male volunteers | solution | cyp2d6 extensive metabolisers | iv | 16984212 | starling | starling_oba | cf95892ec79b8a5fcabfd4146c9ec8276e8cb70ffec728c148593f743c91819c | 58 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | cf95892ec79b8a5fcabfd4146c9ec8276e8cb70ffec728c148593f743c91819c | 2d1160c377ba0b0f82d855efd92bfa2803314088a421988a7d66c89869844e8f | Sample size n = 11; estimation was confounded by large differences in plasma concentrations at oral doses without equivalent intravenous doses. | Overall, the oral bioavailability of traxoprodil in extensive metabolisers ranged from 22.8% to 62.1%. |
NC(=O)N/N=C/c1ccc([N+](=O)[O-])o1 | 114.97 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rabbit | 114.97 | percent | false | Nitrofurazone | absolute | rabbits | 63.5 mg/kg | gavage | null | vs iv | rabbit | rabbits | gavage | not specified | vs iv | 23957951 | starling | starling_oba | d683b0e77d5ffac0b6ce2d21b203e379f20b5bd90a7f694ab17f800592c38fa7 | 59 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | d683b0e77d5ffac0b6ce2d21b203e379f20b5bd90a7f694ab17f800592c38fa7 | 40b0932b7d3c5f27cad66c77d03ebe02e73ae2c8757843352230a700d65a5023 | n=5 subjects | For Nitrofurazone (NF) administered orally at 63.5 mg/kg via gavage, the absolute bioavailability (F absolute) was reported as 114.97% in a study with n=5 subjects, compared to intravenous administration. |
O=C(O)/C=C/C(=O)O.O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1.O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1 | 46.2 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 46.2 | percent | false | (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)-azetidin-1-yl]methanone hemifumarate | absolute | healthy subjects | 20 mg | null | null | 2 mg intravenous infusion | human | healthy subjects | not specified | not specified | 2 mg intravenous infusion | 24010577 | starling | starling_oba | 7d6a65881cd0e0121e8562fb2a437b3d79c15f72630da3051e6e56bc04994063 | 60 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 7d6a65881cd0e0121e8562fb2a437b3d79c15f72630da3051e6e56bc04994063 | 5171a7c2d9fcce9ab6c7dca474bd20e46f74c453b0d1776e57f3642733b70933 | CV 24.2%, n = 13 | In a crossover trial involving 13 healthy subjects, the absolute bioavailability of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)-azetidin-1-yl]methanone hemifumarate (cobimetinib) was 46.2% (CV 24.2%) following a 20 mg oral dose compared to a 2 mg intravenous infusion. |
CC1C2OC3(C)CC(=O)C1CC3(O)O2 | 80 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 80 | percent | false | Paeonimetabolin I | absolute | rats | 0.2 mg/kg | null | null | vs iv | rodent | rats | not specified | not specified | vs iv | 9178932 | starling | starling_oba | f35eb5a34c328388ef54bf0bf020b1b8840df32c1d74687922ee130bee9eefa5 | 61 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | f35eb5a34c328388ef54bf0bf020b1b8840df32c1d74687922ee130bee9eefa5 | d13ab24dcde0409c073886ef1cfd0a26a20714e2821779f1be0a3e3f388e2a4b | Calculated from the AUCs after intravenous and oral administration. | After oral administration of Paeonimetabolin I (PM-I, 2) to rats at a dose of 0.2 mg/kg, the bioavailability (F) was reported as 0.8 ± 0.15. |
CC1C2OC3(C)CC(=O)C1CC3(O)O2 | 107 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 107 | percent | false | Paeonimetabolin I | absolute | rats | 2 mg/kg | null | null | vs iv | rodent | rats | not specified | not specified | vs iv | 9178932 | starling | starling_oba | 9e8dc88a723e2e1a93b7f6d602cca82c1f3cedd27c46ddf3a1b307754dd7ec98 | 62 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 9e8dc88a723e2e1a93b7f6d602cca82c1f3cedd27c46ddf3a1b307754dd7ec98 | eb975b2d618f134d97240ffc0cbe8416625e9ff19a0edd1b6c241a05e8644066 | Calculated from the AUCs after intravenous and oral administration. | After oral administration of Paeonimetabolin I (PM-I, 2) to rats at a dose of 2 mg/kg, the bioavailability (F) was reported as 1.07 ± 0.07. |
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC | 54.6 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | human | 54.6 | percent | false | Fostamatinib | absolute | humans | null | oral | null | null | human | humans | oral | not specified | not specified | 27858108 | starling | starling_oba | 4f0c6c4ebca2fed15fa2a4d1edb1b0ef0389fa42164dfa82f95af0757f9349cd | 63 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 4f0c6c4ebca2fed15fa2a4d1edb1b0ef0389fa42164dfa82f95af0757f9349cd | b56ef855704863b737f3edef2adc87be65e5af925d315a09f0176e3a6facac74 | null | Clinical studies were performed to determine the absolute oral bioavailability of fostamatinib, which was found to be 54.6 %. |
CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1 | 29 | starling.oral_bioavailability.systemic_availability.percent | oral_bioavailability | systemic_availability | percent | human | 29 | percent | false | Loxapine | systemic availability | humans | null | null | null | null | human | humans | not specified | not specified | not specified | 15359567 | starling | starling_oba | 3ba3faeed353e2bd23bbd25ef90eb30aa6593465b9564bb85c66950ae1f2391c | 64 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 3ba3faeed353e2bd23bbd25ef90eb30aa6593465b9564bb85c66950ae1f2391c | 5af0700b4d5ae48383a4bd117e26e50833e444dae0068fa3a28fab0027e477fa | The drug is described as highly extracted with a hepatic extraction ratio (EH) of 0.71. | For loxapine, the fraction of the parent drug absorbed into the systemic circulation (F) was estimated as 0.29, indicating that the drug is highly extracted with a hepatic extraction ratio (EH) of 0.71. |
O=S(=O)(c1ccc(O)cc1)c1ccc(O)cc1 | 57.4 | starling.oral_bioavailability.systemic_availability.percent | oral_bioavailability | systemic_availability | percent | pig | 57.4 | percent | false | BPS | systemic availability | male and female piglets (28-42 d) | 40 μg/kg | oral | null | null | pig | male and female piglets (28-42 d) | oral | not specified | not specified | 32853628 | starling | starling_oba | b31c5a4ec0a0ff4e52f7fb27ad14550764fba17d89d85b95fabc6d4c990eea85 | 65 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | b31c5a4ec0a0ff4e52f7fb27ad14550764fba17d89d85b95fabc6d4c990eea85 | 10a861df6fb20cb0b7d78b490d14c116c15660273affa8fef372837134253b61 | ~ 99% of the administered dose was absorbed with the maximum concentration, Cmax, reached at 0.5 h. | In male and female piglets (28–42 d), following a 40 µg/kg oral dose of BPS, the estimated systemic bioavailability was 57.4%, with approximately 99% of the administered dose being absorbed. |
O=S(=O)(c1ccc(O)cc1)c1ccc(O)cc1 | 62 | starling.oral_bioavailability.systemic_availability.percent | oral_bioavailability | systemic_availability | percent | human | 62 | percent | false | deuterated BPS | systemic availability | human volunteers | 0.1 mg/kg | oral | deuterated bps | null | human | human volunteers | oral | deuterated bps | not specified | 32853628 | starling | starling_oba | 08c3430dcb5f4f8c7b12931c83f2be41045700f788582bc48e081c5bf6e351e8 | 66 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 08c3430dcb5f4f8c7b12931c83f2be41045700f788582bc48e081c5bf6e351e8 | 184ced7af578bbc2ffaf497213d0763be2bcff92f57e44b4ff76f659c56b98ec | Cmax was reached at 0.7 h and 1.1 h for BPS and its glucuronide, respectively, with plasma elimination half-lives of 7.9 h and 9.3 h, respectively. | In a study where six human volunteers were administered 0.1 mg/kg deuterated BPS orally, the estimated systemic bioavailability was 62%. |
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1 | 110 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | cockatiel | 110 | percent | false | celecoxib | absolute | cockatiels (nymphicus hollandicus) | 10 mg/kg bw | oral (po) | standard solution (std) | vs iv | bird | cockatiels (nymphicus hollandicus) | oral (po) | standard solution (std) | vs iv | 28947805 | starling | starling_oba | a603cd83dfdbb2b90e72b653c612fc829891909a54eff582e811510c6aa1620a | 67 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | a603cd83dfdbb2b90e72b653c612fc829891909a54eff582e811510c6aa1620a | 404cf502231102d5612a33e86e6384f48fc5037793d871697ecbbcb91e4fa813 | Dose specified in paragraph 10. | In cockatiels, the absolute oral bioavailability (F%) of celecoxib was 110% when administered as a standard solution (STD). |
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1 | 56 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | cockatiel | 56 | percent | false | celecoxib | absolute | cockatiels (nymphicus hollandicus) | 10 mg/kg bw | oral (po) | commercial formulation (cf) | vs iv | bird | cockatiels (nymphicus hollandicus) | oral (po) | commercial formulation (cf) | vs iv | 28947805 | starling | starling_oba | 0d4966e9c5499f6974222087a8b5f71d8a9f3a402ca506798c8154f152587acb | 68 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 0d4966e9c5499f6974222087a8b5f71d8a9f3a402ca506798c8154f152587acb | b7d57bf5728be511f5116ce51734bed5f76312ed8c3e39306e45cab9b277d28b | Dose specified in paragraph 10. | In cockatiels, the absolute oral bioavailability (F%) of celecoxib was 56% when administered as a commercial formulation (CF). |
NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1 | 113 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | cockatiel | 113 | percent | false | mavacoxib | absolute | cockatiels (nymphicus hollandicus) | 4 mg/kg bw | oral (po) | standard solution (std) | vs iv | bird | cockatiels (nymphicus hollandicus) | oral (po) | standard solution (std) | vs iv | 28947805 | starling | starling_oba | 1ce7a12c71bd155da8638eda7478a0584fd7dfa3e9bd56558eed054809e3bee9 | 69 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 1ce7a12c71bd155da8638eda7478a0584fd7dfa3e9bd56558eed054809e3bee9 | 23b0f98dfb34219b00aaa32a88d5c371a05977750c2a654c06a88285aa8cf87c | Dose specified in paragraph 16. | For mavacoxib in cockatiels, the absolute oral bioavailability (F%) was 113% for the standard solution (STD). |
NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1 | 111 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | cockatiel | 111 | percent | false | mavacoxib | absolute | cockatiels (nymphicus hollandicus) | 4 mg/kg bw | oral (po) | commercial formulation (cf) | vs iv | bird | cockatiels (nymphicus hollandicus) | oral (po) | commercial formulation (cf) | vs iv | 28947805 | starling | starling_oba | 2dfaba166e74c63bbbdb67e8fcb01ba6855f714223bde96079e0d972c0ef921e | 70 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 2dfaba166e74c63bbbdb67e8fcb01ba6855f714223bde96079e0d972c0ef921e | 097d7bc644f9afec77d525aa892457b965ff77af7b846fc77c9e3172da5737ad | Dose specified in paragraph 16. | For mavacoxib in cockatiels, the absolute oral bioavailability (F%) was 111% for the commercial formulation (CF). |
O=c1c(-n2ccnn2)c[nH]n1-c1cc(N2CCOCC2)ncn1 | 59 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 59 | percent | false | molidustat | absolute | healthy male participants | null | immediate release tablets | null | intravenous administration | human | healthy male participants | immediate release tablets | not specified | intravenous administration | 32248614 | starling | starling_oba | e235def906deb6453e735fda3eef80db2a235505a195ae7ee5a73155015b6cf6 | 71 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | e235def906deb6453e735fda3eef80db2a235505a195ae7ee5a73155015b6cf6 | 29f9552a151cc042d2afc7c47a8c756b04b329138abeccec234854eb085b20a1 | Reported in Study 2. | In Study 2, which investigated healthy male participants, orally administered molidustat immediate release tablets had an absolute bioavailability of 59%. |
O=c1c(-n2ccnn2)c[nH]n1-c1cc(N2CCOCC2)ncn1 | 34 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 34 | percent | false | molidustat | absolute | rat | null | null | null | null | rodent | rat | not specified | not specified | not specified | 32248614 | starling | starling_oba | bbe3edfe47a0fa288e27d1104de07082964ed12f0de45c9d7af83c482605e4f8 | 72 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | bbe3edfe47a0fa288e27d1104de07082964ed12f0de45c9d7af83c482605e4f8 | 23664f8cc11d6ef45ad3273d237b01a4205d1a5db1322009799a55a139c3956d | null | The absolute bioavailability (F) of molidustat varies among species, including 34% in rat. |
O=c1c(-n2ccnn2)c[nH]n1-c1cc(N2CCOCC2)ncn1 | 61 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 61 | percent | false | molidustat | absolute | monkey | null | null | null | null | monkey | monkey | not specified | not specified | not specified | 32248614 | starling | starling_oba | b6925b24bd4272be87c22ee73348eb5986189626049e9742c7c12b6d5f27c1ce | 73 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | b6925b24bd4272be87c22ee73348eb5986189626049e9742c7c12b6d5f27c1ce | 472aa928721505f927eb00cf11897271147ede02bcb734f6e8ddcc74716e8e49 | null | The absolute bioavailability (F) of molidustat varies among species, including 61% in monkey. |
O=c1c(-n2ccnn2)c[nH]n1-c1cc(N2CCOCC2)ncn1 | 71 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | dog | 71 | percent | false | molidustat | absolute | dog | null | null | null | null | dog | dog | not specified | not specified | not specified | 32248614 | starling | starling_oba | a64fcce1d44b4bfb8557fcf1edfc8f22c6328f19672d9900731714108adb8188 | 74 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | a64fcce1d44b4bfb8557fcf1edfc8f22c6328f19672d9900731714108adb8188 | 9ba19df34cd633400f767f0d8fabb34dcb4d323f64b903998fcc6043eb5df31c | null | The absolute bioavailability (F) of molidustat varies among species, including 71% in dog. |
CC1=C[C@H]2O[C@@H]3[C@H](O)C[C@](C)([C@@]2(CO)[C@H](O)C1=O)[C@]31CO1 | 19.3 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | chicken | 19.3 | percent | false | deoxynivalenol | absolute | broilers | 0.75 mg/kg bw | bolus | null | intravenously | bird | broilers | bolus | not specified | intravenously | 23099502 | starling | starling_oba | 107ede91fdc74df4cb1b3adbefd87827f6b482041805c00bcf3e4bfaf6a0b391 | 75 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 107ede91fdc74df4cb1b3adbefd87827f6b482041805c00bcf3e4bfaf6a0b391 | 0677ebac0d5b5c338a11bb1996ad9fe90c142d1c2631049a7077909f635b6da4 | The value was described as low. | In broilers, deoxynivalenol administered as a bolus of 0.75 mg/kg BW showed a low absolute oral bioavailability of 19.3%. |
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)C=C[C@H]3[C@H]1C5 | 11 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 11 | percent | false | M6G | absolute | subjects | 20 mg | oral | null | vs iv | human | subjects | oral | not specified | vs iv | 11966664 | starling | starling_oba | 3f4d24257f38ec5eedd9b8e595a920a1e17d165d7ae0608bf72cf931361fbb42 | 76 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 3f4d24257f38ec5eedd9b8e595a920a1e17d165d7ae0608bf72cf931361fbb42 | 55d600b6fbcc2c8991f1ab35d12fc4f06358d7bd08c3a6eaa1d02adac9c90132 | Range 6–15%, 90% CI 9, 12%; calculated using AUC(0,tn). Dose of 20 mg given in 50 ml water. | The overall bioavailability of oral M6G (using AUC(0,tn)) was 11 ± 3% (range 6–15%, 90% CI 9, 12%), with the highest value occurring in the subject with the highest i.v. M6G clearance. |
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)C=C[C@H]3[C@H]1C5 | 4 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 4 | percent | false | M6G | absolute | subjects | 20 mg | oral | directly absorbed oral m6g (contributing to the first plasma m6g peak) | vs iv | human | subjects | oral | directly absorbed oral m6g (contributing to the first plasma m6g peak) | vs iv | 11966664 | starling | starling_oba | 1940ae45de645d6742845bfc95213343c844831d127d64375aebc07397236cf2 | 77 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 1940ae45de645d6742845bfc95213343c844831d127d64375aebc07397236cf2 | b2271b0cf4e333a0a1e7ac575162d313fa4ede28feb5930899852a2b81558fe8 | Range 1–12%. Dose of 20 mg given in 50 ml water. | The bioavailability of directly absorbed oral M6G, contributing to the first plasma M6G peak before the appearance of morphine or M3G, was 4 ± 4% (range 1–12%). |
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1 | 90 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 90 | percent | false | Solifenacin succinate | absolute | healthy adults | null | null | null | null | human | healthy adults | not specified | not specified | not specified | 19566112 | starling | starling_oba | efd005a747cf3fc3cf36f1c2abd48f61cadc59c08cdfe5f59b3e45122a7f3371 | 79 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | efd005a747cf3fc3cf36f1c2abd48f61cadc59c08cdfe5f59b3e45122a7f3371 | e3f6fb54f5e3e3e827e4f608069b61e263cd93740593198148e7a13b78e7cd30 | Bioavailability does not decrease with concomitant food intake. | Studies in healthy adults have shown that solifenacin succinate has a high absolute bioavailability of about 90%, which does not decrease with concomitant food intake. |
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1 | 100 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 100 | percent | false | Etoricoxib | absolute | healthy subjects | 120-mg | tablet | fasted state | vs iv | human | healthy subjects | tablet | fasted state | vs iv | 12638395 | starling | starling_oba | 714a73f8bc01712d29a683e78fabe93672c56305658d4081017d421dd5636977 | 80 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 714a73f8bc01712d29a683e78fabe93672c56305658d4081017d421dd5636977 | a90020043bbcfe0a27e7e2a1da9f4f9584b91c83c30d3c33d5cf927fe1e132d8 | Bioavailability was estimated to be 100% based on a comparison between a 120-mg tablet and a 25-mg IV dose in healthy subjects. | Etoricoxib administered as a 120-mg tablet was rapidly and completely absorbed and available, with the absolute bioavailability estimated to be 100%. |
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1 | 4.2 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 4.2 | percent | false | Cilostazol | absolute | male rats | 0.5 mg/kg | oral administration | null | vs iv | rodent | male rats | oral administration | not specified | vs iv | 21718207 | starling | starling_oba | d2e8d0eef267c0a90e08dd5650557dab2c276a2bf8f8d269687dab47f88d89d1 | 81 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | d2e8d0eef267c0a90e08dd5650557dab2c276a2bf8f8d269687dab47f88d89d1 | 098cc8bd8cbef9e33daa93830db25747879b5f7d7b2520d4ffd2c3001f8ba360 | calculated utilizing the results of in vivo intravenous administration study | The absolute bioavailability after oral dosing of 0.5 mg/kg of cilostazol was calculated to be 4.2 ± 1.2% in male rats. |
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1 | 6.4 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 6.4 | percent | false | Cilostazol | absolute | male rats | 1 mg/kg | oral administration | null | vs iv | rodent | male rats | oral administration | not specified | vs iv | 21718207 | starling | starling_oba | 34e9d2ff87e764f95b27a0b752e06947bcf2cd4303a2277a684675afd4bee893 | 82 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 34e9d2ff87e764f95b27a0b752e06947bcf2cd4303a2277a684675afd4bee893 | 82b5b24ae97e59efc45263b8fea668f2cbd582594026e4475013122dc2bd6ccf | calculated utilizing the results of in vivo intravenous administration study | The absolute bioavailability after oral dosing of 1 mg/kg of cilostazol was calculated to be 6.4 ± 0.7% in male rats. |
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1 | 21.1 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 21.1 | percent | false | Cilostazol | absolute | female rats | 0.5 mg/kg | oral administration | null | vs iv | rodent | female rats | oral administration | not specified | vs iv | 21718207 | starling | starling_oba | bea5d2023871894e33645ff0b19bbbae2afb15097bad71af042c1bd1e4ecf59e | 83 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | bea5d2023871894e33645ff0b19bbbae2afb15097bad71af042c1bd1e4ecf59e | ba655da8a045a9f40d034ab817663592de734067011daaf8a978b7b949429c15 | calculated utilizing the results of in vivo intravenous administration study | The absolute bioavailability after oral dosing of 0.5 mg/kg of cilostazol was calculated to be 21.1 ± 6.1% in female rats. |
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1 | 37.2 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 37.2 | percent | false | Cilostazol | absolute | female rats | 1 mg/kg | oral administration | null | vs iv | rodent | female rats | oral administration | not specified | vs iv | 21718207 | starling | starling_oba | 15126758149825a7dec6502358b891c9429676175f37fd17c0e8501722905593 | 84 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 15126758149825a7dec6502358b891c9429676175f37fd17c0e8501722905593 | dd93e9476d11ad7ee785a220eb5a2c2e4ee53bf9f84078da38cd02a664d82c08 | calculated utilizing the results of in vivo intravenous administration study | The absolute bioavailability after oral dosing of 1 mg/kg of cilostazol was calculated to be 37.2 ± 2.8% in female rats. |
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2 | 94.1 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 94.1 | percent | false | mycophenolic acid | absolute | healthy volunteers | 1.5 g | oral | administered as prodrug mycophenolate mofetil | vs intravenous route | human | healthy volunteers | oral | administered as prodrug mycophenolate mofetil | vs intravenous route | 8728345 | starling | starling_oba | 0f7a0118e1a30b26436f171fbf0ad078700969b8a05b6dcda7d11d7d7d21ad53 | 85 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 0f7a0118e1a30b26436f171fbf0ad078700969b8a05b6dcda7d11d7d7d21ad53 | 2ba0c95ec60da843a8cd0a2bb956a63a3791f04e7e455c09b5404920985de90a | The bioavailability was estimated based on the total area under the concentration-time curve (AUC) and was found to be statistically equivalent (80-120 rule) between routes. | In a study of 12 healthy volunteers, the mean bioavailability of mycophenolic acid (MPA) following oral administration of a 1.5-g dose of the prodrug mycophenolate mofetil (MMF) was estimated as 94.1% relative to the intravenous route. |
CC1=C[C@H]2O[C@@H]3[C@H](O)C[C@](C)([C@@]2(CO)[C@H](O)C1=O)[C@]31CO1 | 70.5 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | pig | 70.5 | percent | false | DON | absolute | pigs | 100 μg/kg | gavage | null | vs iv | pig | pigs | gavage | not specified | vs iv | 26633505 | starling | starling_oba | 6164ae60dc2462aa717d525af889b22fdbb18c7551fac320363e0f4a5c6534c7 | 89 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 6164ae60dc2462aa717d525af889b22fdbb18c7551fac320363e0f4a5c6534c7 | 6d0aa018115a4eed39bd24ffdda8326fbc05ae43926fb72590a2460ce7faa5d4 | Estimated by deconvolution analysis. | Deconvolution analysis estimated the absolute bioavailability of DON in pigs at 70.5% ± 25.6% after oral administration of 100 µg/kg. |
Cc1cccc2sc3nncn3c12 | 93.9 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 93.9 | percent | false | tricyclazole | absolute | male fischer 344 rats | 2 mg/kg | oral | null | vs iv | rodent | male fischer 344 rats | oral | not specified | vs iv | 31461669 | starling | starling_oba | 9f3a37358c9201c65ac3a8985ae58ad6d35771cb702aaeeabd31934963412bf7 | 92 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 9f3a37358c9201c65ac3a8985ae58ad6d35771cb702aaeeabd31934963412bf7 | ce8abbc68b583ab6aeb7c212eed8779ba98589e696fd446f2925c2ba82c2286a | AUC₀–96hr was 11.7 µg h/mL for oral dosing and 12.5 µg h/mL for I.V. injection. | In a study by Johnson et al. (2014), Male Fischer 344 rats were administered tricyclazole at a dose of 2 mg/kg either orally or intravenously. The absolute bioavailability value determined for tricyclazole in this study is 93.9%. |
O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O | 61 | starling.oral_bioavailability.systemic_availability.percent | oral_bioavailability | systemic_availability | percent | rat | 61 | percent | false | dicumarol | systemic availability | rat | 50 mg/kg | po | intravenous phenobarbital treatment (75 mg/kg/day iv beginning 5 days before dicumarol administration) | vs iv | rodent | rat | po | intravenous phenobarbital treatment (75 mg/kg/day iv beginning 5 days before dicumarol administration) | vs iv | 90143 | starling | starling_oba | 4fbebb12880d5ceb668bda7d0112c7ef4abaaaa3c7b102987d2f56d8c2cc4f9e | 93 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 4fbebb12880d5ceb668bda7d0112c7ef4abaaaa3c7b102987d2f56d8c2cc4f9e | 5b7e2e05ee19c78211045d3103bf6f21edb01a17eeab70fbbe22f40ad3ca4bc9 | Determined by simultaneous administration of unlabeled dicumarol orally and 14C-dicumarol intravenously. | Intravenous phenobarbital reduced the extent of absorption of orally administered dicumarol (50 mg/kg po) to 61% of the dose in rats. |
OC[C@@H]1CC[C@H](n2cnc3c(O)ncnc32)O1 | 43 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 43 | percent | false | didanosine | absolute | patients with aids and advanced aids-related complex | 0.8 to 10.2 mg/kg | solution with an antacid | null | iv | human | patients with aids and advanced aids-related complex | solution with an antacid | not specified | iv | 1903100 | starling | starling_oba | 4b20e7f09978865dbec779cf1a740f0d4f96f0b064156163b89bd79cd7685d26 | 94 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 4b20e7f09978865dbec779cf1a740f0d4f96f0b064156163b89bd79cd7685d26 | fc16f951637d0bf0ce22c3dee745008806815b856626b1333ad02dcac1f7b9e8 | Oral bioavailability was determined by evaluating pharmacokinetics after both intravenous and oral administration. | Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex. |
C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1 | 79.6 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 79.6 | percent | false | Traxoprodil | absolute | cyp2d6 poor metabolisers | 50mg | null | null | vs iv | null | cyp2d6 poor metabolisers | not specified | not specified | vs iv | 16984212 | starling | starling_oba | 7c3f04f68210629de1a4dc9330ff0a8383118457a63691fe537ebb63f53d58c0 | 97 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 7c3f04f68210629de1a4dc9330ff0a8383118457a63691fe537ebb63f53d58c0 | f8f81efbf0b5f2e424df45734d71916eefe113e9ba03a69dce0ffbfe92319c65 | Reported in Table IV; text in [p:62] describes bioavailability as similar (~80%) at the two oral doses. | In CYP2D6 poor metabolisers, the absolute oral bioavailability (F) of Traxoprodil was 79.6% following a 50mg oral dose. |
C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1 | 84.7 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 84.7 | percent | false | Traxoprodil | absolute | cyp2d6 poor metabolisers | 100mg | null | null | vs iv | null | cyp2d6 poor metabolisers | not specified | not specified | vs iv | 16984212 | starling | starling_oba | 06884e57fb517cd0c43ecdf43d02014fc1142db987c40402a31c3984518e0343 | 98 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 06884e57fb517cd0c43ecdf43d02014fc1142db987c40402a31c3984518e0343 | b5ef8707ea2cc95e5d76b29260aa49c3c359cc5255cf17ddbb697ab531ca882c | Reported in Table IV; text in [p:62] describes bioavailability as similar (~80%) at the two oral doses. | In CYP2D6 poor metabolisers, the absolute oral bioavailability (F) of Traxoprodil was 84.7% following a 100mg oral dose. |
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1 | 31 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 31 | percent | false | Nilotinib | absolute | null | null | oral | null | null | null | null | 21827214 | starling | starling_oba | 3476626070ea60671ba2bffac8c381a80311934f44dff1828330c24353064eaa | 99 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 3476626070ea60671ba2bffac8c381a80311934f44dff1828330c24353064eaa | e2960ff8888e2b2ca1f2a581616b2bfe315b93742217fcb1d42fb64283c50e6b | bioavailability is substantially increased with food | Following oral administration of nilotinib, a low absolute bioavailability of about 31% is assumed for the drug, although its bioavailability is substantially increased with food. |
[O-][n+]1cccc(-c2nc3c(Cl)cccc3cc2[C@@H](Nc2ncnc3cccnc23)C(F)(F)F)c1 | 97 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 97 | percent | false | seletalisib | absolute | healthy subjects | 30 mg | reference formulation | null | vs iv | human | healthy subjects | reference formulation | not specified | vs iv | 28650526 | starling | starling_oba | 68e28414d936543cfdd6f40fa96ea5a8a0c9a81bb58e1607afa40e6b9303a8ec | 102 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 68e28414d936543cfdd6f40fa96ea5a8a0c9a81bb58e1607afa40e6b9303a8ec | dd63b15d38700dfaf140c3a9307a526a09592c4d39313d36bb3ba52838c0e2f9 | n = 6; reference formulation used | In a study of healthy subjects receiving 30 mg of a reference formulation of seletalisib orally, the absolute oral bioavailability was found to be 97% (90% confidence interval 87, 107). |
NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3 | 69 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 69 | percent | false | Samidorphan | absolute | healthy volunteers | null | null | null | vs iv | human | healthy volunteers | not specified | not specified | vs iv | 31463821 | starling | starling_oba | 76923e17e9741439c95512ed88e5e9a5da967ef8e88d606c2cfdb1f9b75bdc13 | 103 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 76923e17e9741439c95512ed88e5e9a5da967ef8e88d606c2cfdb1f9b75bdc13 | c6eb7284cc4d2600c83692e21aaed2771f2ed2393da4ec923d3701f775ee77bf | Sublingual administration showed an absolute bioavailability of 71%. | In study 1, which involved healthy volunteers, samidorphan was well-absorbed following oral administration and reached peak concentrations within 2 hours, with an absolute bioavailability of 69%. |
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O | 16 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 16 | percent | false | Romidepsin | absolute | rats | 50 mg/kg | p.o. | null | 10 mg/kg iv | rodent | rats | p.o. | not specified | 10 mg/kg iv | 28541045 | starling | starling_oba | 613854779ad0c3050f8d9be6daf62f6fe79bb495f775c4f4c155e3f9974175e8 | 104 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 613854779ad0c3050f8d9be6daf62f6fe79bb495f775c4f4c155e3f9974175e8 | 10c191584869f36e716d241fa2fc259a333ce5909d512002e6a32a1588dfd5b9 | AUC = 19712 ± 9168 ng/mL·min | Romidepsin was significantly absorbed after oral administration to rats; at a dose of 50 mg/kg p.o., the absolute bioavailability (F) was 16 ± 7% with an AUC of 19712 ± 9168 ng/mL·min, compared to a 10 mg/kg iv dose. |
CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CCCNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CC2CCCCC2)NC(=O)[C@@H]2CCCN2C1=O | 1.5 | starling.oral_bioavailability.systemic_availability.percent | oral_bioavailability | systemic_availability | percent | rat | 1.5 | percent | false | 3D53 | systemic availability | rat | null | oral | null | null | rodent | rat | oral | not specified | not specified | 28541045 | starling | starling_oba | 07d432862860b7d6fc90f8b33e994c9c7409c588e0b40e57e302c257fe907dba | 105 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 07d432862860b7d6fc90f8b33e994c9c7409c588e0b40e57e302c257fe907dba | f1b93ee4eb6e88b30ea0d05e8446dfaac10b174639424bc465bfd4f5d91e5df1 | The authors note that oral activity is observed despite this low bioavailability due to long receptor residence time. | Compound 3D53 (16) is described as having low oral bioavailability and low systemic availability (F = 1–2%) in rats. |
O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1 | 72.7 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | human | 72.7 | percent | false | Mitapivat | absolute | humans | null | oral | null | vs iv | human | humans | oral | not specified | vs iv | 37596712 | starling | starling_oba | fc4b95632c7bc3758c7eabcff4ddeff783dcb2dc35bbaba16a55f7723a381a40 | 106 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | fc4b95632c7bc3758c7eabcff4ddeff783dcb2dc35bbaba16a55f7723a381a40 | 3329432b97e80014a85c50702ea4c7ae471e2bf625aad8091ee1d2273e14bd72 | 8.80% CV | The absolute oral bioavailability of mitapivat in humans was high, reported as 72.7% (8.80% CV). |
O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1 | 65.3 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | human | 65.3 | percent | false | Mitapivat | absolute | humans | null | oral | null | vs iv | human | humans | oral | not specified | vs iv | 37596712 | starling | starling_oba | 10f2441db29ce3960158eefa859e36e016e748c8b706efe7760ed0241b9802d6 | 107 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 10f2441db29ce3960158eefa859e36e016e748c8b706efe7760ed0241b9802d6 | 8df6e928875d23ebf4734c1219d7df83c3e1d8ba77c1fa251f1ff9c43f75cb75 | Range for individual subjects based on AUC0–∞ or AUC0–last | For individual human subjects, the absolute bioavailability of mitapivat based on AUC0–∞ or AUC0–last ranged from 65.3% to 86.3%. |
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1 | 62 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 62 | percent | false | edoxaban | absolute | null | null | po | null | iv | null | null | 27121940 | starling | starling_oba | 443cf1ffb3aea5b4d911e0c7fe6b3fd256ce3ceaf719c6972f3a7aea8129ceac | 108 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 443cf1ffb3aea5b4d911e0c7fe6b3fd256ce3ceaf719c6972f3a7aea8129ceac | 252adda099815605346b7bc59084233f91ed91fa4eba44a521599dd7efa4e9de | The drug was described as rapidly absorbed. | In conclusion, edoxaban is rapidly absorbed, and absolute bioavailability was almost 62% of the PO dose. |
C[S+](CC[C@H](N)C(=O)O)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O | 68.6 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | human | 68.6 | percent | false | SAM | absolute | humans | 2 mg | oral | null | sublingual route | human | humans | oral | not specified | sublingual route | 31463821 | starling | starling_oba | 73d4d61b64e78c106e02b2b25da89a767b6bcdfa4279c6bfbeb04199e5e98861 | 109 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 73d4d61b64e78c106e02b2b25da89a767b6bcdfa4279c6bfbeb04199e5e98861 | 60a640d8c91b4007656d1c11874abde6bad3e547767f2dd5926d8c26fe8c880e | n = 9 | Following the administration of 2 mg SAM, the average absolute bioavailability for the oral route of administration was mean 68.6% (range 60.3–82.6%; n = 9), which was similar to the absolute bioavailability observed for the sublingual route (mean 71.2%; range 62.9–80.3%; n = 10). |
COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC | 54.6 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | human | 54.6 | percent | false | R406 | absolute | humans | 150 mg | tablet | null | 14c-r406 (intravenous) 100 μg in solution | human | humans | tablet | not specified | 14c-r406 (intravenous) 100 µg in solution | 27858108 | starling | starling_oba | f79cff52c8d99cf652143b8e040937cd90c9b5e036e446db057bfc3fc5ca858c | 110 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | f79cff52c8d99cf652143b8e040937cd90c9b5e036e446db057bfc3fc5ca858c | 9905ae2fd8d06bd7dfd306850c020840e3f24d776f721473fceb2ef55b7b917a | Median value reported. Sample size: n=10 for oral and n=9 for intravenous. | In study 27, the oral bioavailability (F) of R406 following administration of a 150 mg tablet was 54.6 (42.4)%, with 14C-R406 (intravenous) 100 µg in solution used as the comparator. |
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 | 66.1 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 66.1 | percent | false | Sertraline | absolute | healthy subjects | null | null | null | vs iv | human | healthy subjects | not specified | not specified | vs iv | 32430638 | starling | starling_oba | 57a8f025e9829b0b43b19fde0ad6656cdf2d69868cd056d3ab554dc3e2062537 | 111 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 57a8f025e9829b0b43b19fde0ad6656cdf2d69868cd056d3ab554dc3e2062537 | bbd52a80b8fd893a2dcc860abcc21d8d807c407b40465e994bef65ea4d9be489 | Fmax represents the maximum bioavailability within a nonlinear bioavailability-dose relationship estimated from clinical PK data. | In Table III, the maximum bioavailability (Fmax) for sertraline is reported with an estimate of 0.639 (8% RSE) and a SIR median of 0.661 (95% CI: 0.559–0.804). |
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1 | 65 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 65 | percent | false | Canagliflozin | absolute | healthy participants | 300 mg | tablet | fasted conditions | vs iv | human | healthy participants | tablet | fasted conditions | vs iv | 27136910 | starling | starling_oba | 12ee1b2d7a4f65f71cd5802382d6e9b61b6c66adbd78f4b95c7f86b4823981ed | 112 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 12ee1b2d7a4f65f71cd5802382d6e9b61b6c66adbd78f4b95c7f86b4823981ed | 25342a364d76abb6b3ed1662613a5e395e0016c43403921003dd6e3f526ef2a9 | Calculated as a geometric mean ratio of 65% for both AUC∞ and AUClast compared to dose-normalized intravenous [¹⁴C]-canagliflozin. | In healthy participants, the observed mean absolute oral bioavailability of canagliflozin was approximately 65% following a single-dose administration of a 300 mg tablet under fasted conditions. |
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1 | 61.5 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 61.5 | percent | false | 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide | absolute | rats | 1-10 mg kg-1 | oral dosing | null | null | rodent | rats | oral dosing | not specified | not specified | 16308283 | starling | starling_oba | 5ed272e5404d3e9b5252730a74562ecd3c861111a8a67b0bae1d2ca4d8b606b5 | 113 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 5ed272e5404d3e9b5252730a74562ecd3c861111a8a67b0bae1d2ca4d8b606b5 | 0bcdda23e9811ea2f25f8cd4955939f8c97cf071212241831e6c2132682323e1 | null | BAY 59-7939 was rapidly absorbed after oral dosing, with an absolute bioavailability of 57–66% in rats. Plasma pharmacokinetics of BAY 59-7939 were linear across the investigated dose range of 1–10 mg kg⁻¹ in rats. |
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1 | 73 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | dog | 73 | percent | false | 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide | absolute | dogs | 0.3-3 mg kg-1 | oral dosing | null | null | dog | dogs | oral dosing | not specified | not specified | 16308283 | starling | starling_oba | 72195098895ae7d9f656a3781033c4d2c3caee4eca88f453254cdbc5b3e176b0 | 114 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 72195098895ae7d9f656a3781033c4d2c3caee4eca88f453254cdbc5b3e176b0 | c0b34627cfeae279e97c34af67025968f77286ad2b6907ad269f8b9c14527d23 | null | BAY 59-7939 was rapidly absorbed after oral dosing, with an absolute bioavailability of 60–86% in dogs. Plasma pharmacokinetics of BAY 59-7939 were linear across the investigated dose range of 0.3–3 mg kg⁻¹ in dogs. |
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C | 5.2 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 5.2 | percent | false | Atorvastatin | absolute | rats | 10 mg/kg | single oral dose | null | vs iv | rodent | rats | single oral dose | not specified | vs iv | 16624870 | starling | starling_oba | 56eae95f3342a7bbb0e082b7a2194aa832deb793281ad5eb42418091d668a123 | 115 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 56eae95f3342a7bbb0e082b7a2194aa832deb793281ad5eb42418091d668a123 | 7140e34fe87c03827a0cd956f1ca17978e6b79a06ff89ca5c8f6ff47dec7f80f | Sample size n = 5; also described in text as 5.2%. | In rats (n = 5) receiving a single oral dose of 10 mg/kg atorvastatin (ATV) alone, the oral bioavailability (F) was 0.052 ± 0.020. |
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C | 14 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 14 | percent | false | Atorvastatin | absolute | rats | 10 mg/kg | single oral dose | coadministered with bolus intravenous rifampicin (20 mg/kg) | vs iv | rodent | rats | single oral dose | coadministered with bolus intravenous rifampicin (20 mg/kg) | vs iv | 16624870 | starling | starling_oba | 51420ca8b022df20e31dc9a6d428606dd965faf47dfebe6c05d4efe037140545 | 116 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 51420ca8b022df20e31dc9a6d428606dd965faf47dfebe6c05d4efe037140545 | 59ad69c5944e39e6e9ff3adaacf9c04e9044966befc662d5aa5cea921cf77050 | Sample size n = 5; also described in text as 14%. | In rats (n = 5) receiving a single oral dose of 10 mg/kg atorvastatin (ATV) with a bolus intravenous dose of 20 mg/kg rifampicin (RIF), the oral bioavailability (F) was 0.14 ± 0.03. |
CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O | 30 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 30 | percent | false | erythromycin stearate | absolute | healthy volunteers | 250 mg | film-coated tablets | 1 h before meals | vs i.v. injections | human | healthy volunteers | film-coated tablets | 1 h before meals | vs i.v. injections | 7306427 | starling | starling_oba | 9d4fdba01392558cd1c55a68352681aedf7b7c18551cdf9a74047b2ca4945a05 | 117 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 9d4fdba01392558cd1c55a68352681aedf7b7c18551cdf9a74047b2ca4945a05 | b87ba8a1f9f0414893f070dfce6d0a03e4a45f4d656117964f2d0585cbe2754c | Dose 1; 24 healthy volunteers | In a study of 24 healthy volunteers, the absolute bioavailability of erythromycin stearate tablets (Regimen A), administered 1 hour before meals at a dose of 250 mg, was approximately 30% for Dose 1. |
CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O | 65 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 65 | percent | false | erythromycin stearate | absolute | healthy volunteers | 250 mg | film-coated tablets | 1 h before meals | vs i.v. injections | human | healthy volunteers | film-coated tablets | 1 h before meals | vs i.v. injections | 7306427 | starling | starling_oba | f430e3b0f7637c827c18a55394f56cf13c2df4fbdaa391361ea7d37567e0c5e6 | 118 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | f430e3b0f7637c827c18a55394f56cf13c2df4fbdaa391361ea7d37567e0c5e6 | 875eca97ae00259cda9d8a4fc1c9d85ab71bfc614567afb07606d1c0eeb9b90b | Dose 9 (steady-state); 24 healthy volunteers | In a study of 24 healthy volunteers, the absolute bioavailability of erythromycin stearate tablets (Regimen A), administered 1 hour before meals at a dose of 250 mg, was 65% for Dose 9. |
CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O | 40 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 40 | percent | false | erythromycin base | absolute | healthy volunteers | 250 mg | enteric-coated capsules | 30 min after start of meals | vs i.v. injections | human | healthy volunteers | enteric-coated capsules | 30 min after start of meals | vs i.v. injections | 7306427 | starling | starling_oba | 8d3c6a2d085a8273adaf13446b40d3e91f74e69f77d4819b4958b106f39e5c86 | 119 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 8d3c6a2d085a8273adaf13446b40d3e91f74e69f77d4819b4958b106f39e5c86 | 5825010cb02fcaeb3ccf1921cd1dc41940b88d794f2a148ac25e7a37a9fac5f8 | Reported for both Dose 1 and Dose 9; 24 healthy volunteers | For Regimen B, consisting of erythromycin base capsules administered 30 minutes after the start of meals at a dose of 250 mg, the absolute bioavailability was 40% for both Dose 1 and Dose 9 in 24 healthy volunteers. |
CN(C)CCO[C@]1(c2ccccc2)C[C@H]2CC[C@]1(C)C2(C)C | 56 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 56 | percent | false | deramciclane | absolute | null | 1 mg kg-1 | oral | deramciclane fumarate | vs iv | null | null | 9840215 | starling | starling_oba | fd92e80256adf78afef91a6da0af495dce269356ae37a201c02e2ee799ba5505 | 122 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | fd92e80256adf78afef91a6da0af495dce269356ae37a201c02e2ee799ba5505 | 5855ce709b5779346100a61172b9c4f503437e5dc530eb84479884926862c2b4 | null | The absolute bioavailabilities of deramciclane were 56 (10)% for a 1 mg kg⁻¹ dose. |
CN(C)CCO[C@]1(c2ccccc2)C[C@H]2CC[C@]1(C)C2(C)C | 45 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 45 | percent | false | deramciclane | absolute | null | 3 mg kg-1 | oral | deramciclane fumarate | vs iv | null | null | 9840215 | starling | starling_oba | 5c5a99dcbbb3ad37a6eebf7e679beccfb3e1725dfd16b733d2ab2eb112425143 | 123 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 5c5a99dcbbb3ad37a6eebf7e679beccfb3e1725dfd16b733d2ab2eb112425143 | 2cf3564109ae919f976f81186edd5b9848d542c4de758c890038c5639aa93de4 | null | The absolute bioavailabilities of deramciclane were 45 (5.9)% for a 3 mg kg⁻¹ dose. |
CN(C)CCO[C@]1(c2ccccc2)C[C@H]2CC[C@]1(C)C2(C)C | 61 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 61 | percent | false | deramciclane | absolute | null | 6 mg kg-1 | oral | deramciclane fumarate | vs iv | null | null | 9840215 | starling | starling_oba | 27ee03713de102a991e21e62a13cb03e5c6032909e383cf61b3ef280a76eef74 | 124 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 27ee03713de102a991e21e62a13cb03e5c6032909e383cf61b3ef280a76eef74 | fb0a4f865dc9b229ef91d31b51928a403727d0b7f3968b2d2f08589f692204c1 | null | The absolute bioavailabilities of deramciclane were 61 (14)% for a 6 mg kg⁻¹ dose. |
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1 | 100 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 100 | percent | false | Etoricoxib | absolute | healthy subjects | 120 mg | tablet | null | null | human | healthy subjects | tablet | not specified | not specified | 12638395 | starling | starling_oba | aeb4c3c7211ddc04d987bacbb9afdd4110cae8885e0641c80a9aade9b1e69c52 | 125 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | aeb4c3c7211ddc04d987bacbb9afdd4110cae8885e0641c80a9aade9b1e69c52 | 0523bf6d41a22e86130df6559843184adf2acf06b321800b011bc49c140789f7 | Reported for the highest dose-strength tablet; authors infer that lower dose-strength tablets (60, 90 mg) are also completely absorbed. | Etoricoxib was found to be essentially completely absorbed and available following administration of the highest dose-strength tablet (120 mg), with an estimated absolute bioavailability of approximately 100% in healthy subjects. |
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1 | 100 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | null | 100 | percent | false | Etoricoxib | absolute | healthy subjects | 120 mg | tablet | high-fat meal | null | human | healthy subjects | tablet | high-fat meal | not specified | 12638395 | starling | starling_oba | 7442ff3254b3ec66e6a8d9f0afedd5b3efb89e2b68a55ea75387117ff9f064ec | 126 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 7442ff3254b3ec66e6a8d9f0afedd5b3efb89e2b68a55ea75387117ff9f064ec | 22ff0ba43a564641831513e59f556b85e06ca2d38236951a9b794b3b77308f89 | High-fat meal decreased the rate of absorption (Cmax 36% lower and delayed) but did not affect the extent of absorption (AUC infinity). | Administration of the 120-mg tablet of etoricoxib following a high-fat meal had no effect on the extent of absorption, consistent with the compound's 100% bioavailability. |
CC12CCCC(O)(C1)C1CC(C)(C)C1CC2 | 1.17 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 1.17 | percent | false | $\beta$-caryophyllene alcohol | absolute | rats | null | solution | null | vs iv | rodent | rats | solution | not specified | vs iv | 28891397 | starling | starling_oba | 05220e6912b94bfb7c2bc85e907a97d5bc20d2d5c0a35dce5c5479bac2e3720c | 129 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 05220e6912b94bfb7c2bc85e907a97d5bc20d2d5c0a35dce5c5479bac2e3720c | 90cdb0b6259f7a0e66e54509b65b4bfb1dd0c1383a3b173d0a64f8b88ac6db61 | described as low | In rats, the measured oral bioavailability of $\beta$-caryophyllene alcohol (BCPA) was low for the solution formulation, reported as 1.17 ± 0.78%. |
CC12CCCC(O)(C1)C1CC(C)(C)C1CC2 | 1.21 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 1.21 | percent | false | $\beta$-caryophyllene alcohol | absolute | rats | null | suspension | null | vs iv | rodent | rats | suspension | not specified | vs iv | 28891397 | starling | starling_oba | 391e57ff610898c94dc2dbebad54c59a54aaf19db50df824e082ac5c9cf87314 | 130 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 391e57ff610898c94dc2dbebad54c59a54aaf19db50df824e082ac5c9cf87314 | 35030ecbbfd71943907d6a0371a4f9897e53a1bd4f2abcd260ba91cd31cae995 | described as low | In rats, the measured oral bioavailability of $\beta$-caryophyllene alcohol (BCPA) was low for the suspension formulation, reported as 1.21 ± 0.33%. |
CC12CCCC(O)(C1)C1CC(C)(C)C1CC2 | 6.22 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | rat | 6.22 | percent | false | $\beta$-caryophyllene alcohol | absolute | rats | null | peg formulation | null | vs iv | rodent | rats | peg formulation | not specified | vs iv | 28891397 | starling | starling_oba | c74d90c7e7f7a7c6f326b9321b6a11b2bed7d51b42fc8c8bfc3b280c9efaa0dc | 131 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | c74d90c7e7f7a7c6f326b9321b6a11b2bed7d51b42fc8c8bfc3b280c9efaa0dc | 322da4c82f29e9794c5df71a9162a183f7b9d1d2485460ee8960c48e05cdf00f | described as low | In rats, the measured oral bioavailability of $\beta$-caryophyllene alcohol (BCPA) was low for the PEG formulation, reported as 6.22 ± 2.63%. |
CC12CCCC(O)(C1)C1CC(C)(C)C1CC2 | 0.12 | oral_bioavailability.absolute.percent | oral_bioavailability | absolute | percent | dog | 0.12 | percent | false | $\beta$-caryophyllene alcohol | absolute | dogs | null | solution | null | vs iv | dog | dogs | solution | not specified | vs iv | 28891397 | starling | starling_oba | 98064657b1c53d616ed24f8b2ff60ec735afa561bf58665e96ab991f17f76089 | 132 | 2068cd431e76155d0c7f61a9eb45a2ba64eaa8d77c7a19c966a70a294079dceb | 98064657b1c53d616ed24f8b2ff60ec735afa561bf58665e96ab991f17f76089 | 51c51301ab7fbc37cb1a41c19bd203911b9e8c9bac29ba2923123757e1b1f76a | reported as lower than in rats | The bioavailability of $\beta$-caryophyllene alcohol was lower in dogs for the solution formulation, reported as 0.12 ± 0.05%. |
End of preview. Expand in Data Studio
Starling Oba Cleaned
This dataset contains 27,640 accepted finite scalar measurement children from the versioned canonical-base pipeline. A parent row with several unambiguous measurements can produce several child rows. Rejected, malformed, ambiguous, bounded, range-only, TDC-overlapping, and endpoint-unassignable records are not published here.
Cleaning
The following source columns are replaced in place with validated canonical or lexical normalizations:
smiles→canonical_smilesbioavailability_report_type→bioavailability_report_type_normalizedspecies_or_population→species_or_population_mechanical_normalizeddose→dose_normalizedoral_exposure_mode→oral_exposure_mode_normalizedqualifying_conditions→qualifying_conditions_normalizedcomparator→comparator_normalizedoral_bioavailability_value→scalar_value
The public column names on the left are retained; the names on the right identify the validated internal values used to replace them. Columns omitted from this dataset:
direction:all_null_in_datasettarget:all_null_in_datasetkinetic_parameter:all_null_in_datasetauc_window:all_null_in_datasetdefining_timepoint:all_null_in_datasetvariation_value:all_null_in_datasetvariation_type:all_null_in_datasetaccompanying_interval_lower:all_null_in_datasetaccompanying_interval_upper:all_null_in_dataset
canonical_endpoint_key is the endpoint identity field. No condition_key is added.
species_exact is populated only for explicit, unambiguous species references. Narrative
and other source fields without a validated normalization remain source text.
- Downloads last month
- 43